.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Fuji
Cantor Fitzgerald
Daiichi Sankyo
Boehringer Ingelheim
Cipla
Novartis
Healthtrust
Cerilliant
Federal Trade Commission

Generated: June 24, 2017

DrugPatentWatch Database Preview

FLOMAX Drug Profile

« Back to Dashboard

What is the patent landscape for Flomax, and what generic Flomax alternatives are available?

Flomax is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in FLOMAX is tamsulosin hydrochloride. There are thirty-two drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the tamsulosin hydrochloride profile page.

Summary for Tradename: FLOMAX

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list113
Clinical Trials: see list36
Patent Applications: see list1,233
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FLOMAX at DailyMed

Pharmacology for Tradename: FLOMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
FLOMAX
tamsulosin hydrochloride
CAPSULE;ORAL020579-001Apr 15, 1997ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FLOMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
FLOMAX
tamsulosin hydrochloride
CAPSULE;ORAL020579-001Apr 15, 19974,868,216► Subscribe
Boehringer Ingelheim
FLOMAX
tamsulosin hydrochloride
CAPSULE;ORAL020579-001Apr 15, 19974,703,063*PED► Subscribe
Boehringer Ingelheim
FLOMAX
tamsulosin hydrochloride
CAPSULE;ORAL020579-001Apr 15, 19974,772,475► Subscribe
Boehringer Ingelheim
FLOMAX
tamsulosin hydrochloride
CAPSULE;ORAL020579-001Apr 15, 19974,731,478► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FLOMAX

Drugname Dosage Strength RLD Submissiondate
tamsulosin hydrochlorideCapsules0.4 mgFlomax12/20/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Chubb
QuintilesIMS
US Department of Justice
AstraZeneca
Cantor Fitzgerald
Accenture
Express Scripts
Queensland Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot